BioCT, the state’s quasi-public bioscience ecosystem support group, has named two new members to its board of directors.
Mostafa Analoui is executive director of the Venture Development & Technology Incubation Program at the University of Connecticut. Previously, he was head of health care and life sciences at Livingston Securities in New York, with investment focus in private and public companies in biotech, medtech and health-care services. Before that he was senior director at Pfizer Global Research and Development. He received a Ph.D. from Purdue University, followed by a post-doctoral fellowship at IBM T.J. Watson Research Center in New York.
Carine Boustany is U.S. department head of cardiometabolic diseases research at Boehringer Ingelheim. Before joining BI in 2011, Boustany was a researcher at Pfizer, where she led project teams in diabetes and diabetic nephropathy. She earned a PharmD degree from Saint-Joseph University (Beirut, Lebanon), followed by a Ph.D. in pharmaceutical sciences from the College of Pharmacy at the University of Kentucky and a post-doctoral fellowship at the same school.
